Psychedelics

Latest News

psilocybin
COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

June 23rd 2025

Compass Pathways reports significant progress in psilocybin research, showing promise for treatment-resistant depression in a pivotal phase 3 trial.

brain scan
What’s Perfusion Got to Do With It?

May 12th 2025

clinical trial
MindMed Begins Phase 3 Emerge Study of MM120 in Patients With Major Depressive Disorder

April 21st 2025

COVID
Psilocybin Benefits Clinicians Traumatized on Front Line of COVID-19 Pandemic

March 11th 2025

Psychiatric Times Through the Years: The Last 5 Years in February Covers
Psychiatric Times Through the Years: The Last 5 Years in February Covers

February 22nd 2025

Video Interviews
Podcasts
Latest CME Events & Activities

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Real Psychiatry 2026

January 23-24, 2026

View More

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.